Lyell Immunopharma Inc
NASDAQ:LYEL

Watchlist Manager
Lyell Immunopharma Inc Logo
Lyell Immunopharma Inc
NASDAQ:LYEL
Watchlist
Price: 0.6127 USD -4.41%
Market Cap: 171.1m USD
Have any thoughts about
Lyell Immunopharma Inc?
Write Note

Lyell Immunopharma Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lyell Immunopharma Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Lyell Immunopharma Inc
NASDAQ:LYEL
Pre-Tax Income
-$234.6m
CAGR 3-Years
-5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$7.2B
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$176m
CAGR 3-Years
-73%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$4.7B
CAGR 3-Years
-10%
CAGR 5-Years
-13%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$259.6m
CAGR 3-Years
-54%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5B
CAGR 3-Years
-15%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

Lyell Immunopharma Inc
Glance View

Market Cap
157.2m USD
Industry
Biotechnology

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 219 full-time employees. The company went IPO on 2021-06-17. The firm offers T cells to cure patients with solid tumors. Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors. The company builds a multi-modality product pipeline across solid tumor indications with unmet needs and anticipate having investigational new drug application (IND). The company offers Gen-R and Epi-R technology platforms. Its Gen-R is its ex vivo genetic reprogramming technology to overcome T cell exhaustion. Its Epi-R is an ex vivo epigenetic reprogramming technology to create a population of T cells with durable stemness. Epi-R is designed to generate populations of T cells which have this property of durable stemness. The company utilizes its Gen-R and Epi-R technology platforms to develop a multi-modality product pipeline.

LYEL Intrinsic Value
0.7356 USD
Undervaluation 17%
Intrinsic Value
Price

See Also

What is Lyell Immunopharma Inc's Pre-Tax Income?
Pre-Tax Income
-234.6m USD

Based on the financial report for Dec 31, 2023, Lyell Immunopharma Inc's Pre-Tax Income amounts to -234.6m USD.

What is Lyell Immunopharma Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 3Y
-5%

Over the last year, the Pre-Tax Income growth was -28%. The average annual Pre-Tax Income growth rates for Lyell Immunopharma Inc have been -5% over the past three years .

Back to Top